The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage

Curr Cancer Drug Targets. 2014;14(2):115-27. doi: 10.2174/1568009613666131126115012.

Abstract

Background: The prognosis of the oral squamous cell carcinoma (OSCC) patients remains very poor, mainly due to their high propensity to invade and metastasize. E-cadherin reduced expression occurs in the primary step of oral tumour progression and gene methylation is a mode by which the expression of this protein is regulated in cancers. In this perspective, we investigated E-cadherin gene (CDH1) promoter methylation status in OSCC and its correlation with Ecadherin protein expression, clinicopathological characteristics and patient outcome.

Methods: Histologically proven OSCC and paired normal mucosa were analyzed for CDH1 promoter methylation status and E-cadherin protein expression by methylation-specific polymerase chain reaction and immunohistochemistry. Colocalization of E-cadherin with epidermal growth factor (EGF) receptor (EGFR) was evidenced by confocal microscopy and by immunoprecipitation analyses.

Results: This study indicated E-cadherin protein down-regulation in OSCC associated with protein delocalization from membrane to cytoplasm. Low E-cadherin expression correlated to aggressive, poorly differentiated, high grade carcinomas and low patient survival. Moreover, protein down-regulation appeared to be due to E-cadherin mRNA downregulation and CDH1 promoter hypermethylation. In an in vitro model of OSCC the treatment with EGF caused internalization and co-localization of E-cadherin with EGFR and the addition of demethylating agents increased E-cadherin expression.

Conclusion: Low E-Cadherin expression is a negative prognostic factor of OSCC and is likely due to the hypermethylation of CDH1 promoter. The delocalization of E-cadherin from membrane to cytoplasm could be also due to the increased expression of EGFR in OSCC and the consequent increase of E-cadherin co-internalization with EGFR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD
  • Antimetabolites, Antineoplastic / pharmacology
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Cadherins / genetics*
  • Cadherins / metabolism
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / metabolism
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology
  • Case-Control Studies
  • Cell Line, Tumor
  • DNA Methylation* / drug effects
  • DNA Modification Methylases / antagonists & inhibitors
  • DNA Modification Methylases / metabolism
  • Down-Regulation
  • Enzyme Inhibitors / pharmacology
  • Epigenesis, Genetic* / drug effects
  • ErbB Receptors / metabolism
  • Female
  • Gene Expression Regulation, Neoplastic* / drug effects
  • Genetic Predisposition to Disease
  • Head and Neck Neoplasms / genetics*
  • Head and Neck Neoplasms / metabolism
  • Head and Neck Neoplasms / mortality
  • Head and Neck Neoplasms / pathology
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Mouth Neoplasms / genetics*
  • Mouth Neoplasms / metabolism
  • Mouth Neoplasms / mortality
  • Mouth Neoplasms / pathology
  • Prognosis
  • Promoter Regions, Genetic
  • Protein Transport
  • RNA, Messenger / metabolism
  • Real-Time Polymerase Chain Reaction
  • Squamous Cell Carcinoma of Head and Neck
  • Time Factors

Substances

  • Antigens, CD
  • Antimetabolites, Antineoplastic
  • Biomarkers, Tumor
  • CDH1 protein, human
  • Cadherins
  • Enzyme Inhibitors
  • RNA, Messenger
  • DNA Modification Methylases
  • EGFR protein, human
  • ErbB Receptors